期刊文献+

丙戊酸联合替西罗莫司抑制弥漫大B细胞淋巴瘤细胞生长的机制研究 被引量:3

Mechanism of Inhibiting the Cell Growth in Diffuse Large B-cell Lymphoma by Valproic Acid Combined with Temsirolimus
下载PDF
导出
摘要 本研究探讨联合应用短链脂肪酸类去乙酰化酶(HDAC)抑制剂丙戊酸(VPA)和哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂替西罗莫司(TEM)抑制弥漫大B淋巴瘤细胞生长的机制。应用MTT法检测细胞增殖抑制率,瑞氏染色检测细胞形态学改变,流式细胞术检测细胞凋亡、周期及自噬相关蛋白,透射电子显微镜检测细胞超微结构变化,蛋白质印迹法检测相关蛋白水平。结果表明,单用VPA和TEM均可抑制淋巴瘤细胞增殖,两药合用抑制作用更为显著;流式细胞术检测结果显示,两药联合后可阻断细胞周期,引起自噬相关蛋白LC3表达增高;电子显微镜检测进一步证实,经VPA及TEM处理后的细胞出现自噬体和自噬溶酶体,两药合用时自噬现象更为显著;蛋白质免疫印迹证实,自噬通路相关蛋白的表达发生改变;经VPA处理后HDAC1和HDAC3表达下调,组蛋白乙酰化水平升高,表明VPA可通过表观遗传学调控影响淋巴瘤细胞增殖、促进其自噬。结论:VPA和TEM在阻断淋巴瘤细胞增殖、促进细胞自噬方面具有协同效应,为药物联合治疗提供了新的理论基础,具有良好的临床应用前景。 The aim of this study was to illustrate the mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by histone deacetylase inhibitor valproic acid (VPA) combined with mTOR inhibitor temsirolimus (TEM). MTT assay and Wright's stain were used to assess cell growth inhibition and to detect the cell morphological changes re- spectively. The cell apoptosis, cell cycle and cell autophagy were determined by flow cytometry. Ultrastructttre changes were confirmed by electron microscopy. Protein changes were detected by Western blot. The results showed that both VPA and TEM alone inhibited cell proliferation and the effect was more obvious in the combination group. VPA com- bined with TEM induced cell arrest in G0/G1 phase and upregulated the expression of autophagy-related protein LC3, without cell apoptosis. Moreover, typical autophagosomes were observed, further confirming the presence of autophagy. Western blot showed the changes of proteins involved in autophagy signaling pathway. VPA decreased HDAC1 and HDAC3 expression and increased histone acetylation, suggesting that VPA also affected lymphoma cell proliferation through epigenetic modification. It is concluded that the combined treatment of VPA and TEM induces cell cycle arrest and cell autophagy, which provides a new clue for their clinical application in diffuse large B-cell lymphoma.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2013年第6期1441-1447,共7页 Journal of Experimental Hematology
关键词 去乙酰化酶抑制剂 MTOR抑制剂 自噬 弥漫大B细胞淋巴瘤 丙戊酸 替西罗莫司 histone deacetylase inhibitor mTOR inhibitor autophagy diffuse large B-cell lymphoma
  • 相关文献

参考文献17

  • 1Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. ArchPathol Lab Med, 2008;132( 1) : 118 - 124.
  • 2Gozuacik D, Kimchi A. Autophagy as a cell death and tumor sup-pressor mechanism. Oncogene,2004; 23(16) : 2891 -2906.
  • 3Buchwald M, Kramer OH, Heinzel T. HDACi-targets beyond chro-matin. Cancer Lett, 2009;280(2) : 160 - 167.
  • 4Gammoh N,Lam D,Puente C,et al. Role of autophagy in histonedeacetylase inhibitor-induced apoptotic and nonapoptotic cell death.Proc Natl Acad Sci USA,2012; 109( 17) :6561 -6565.
  • 5Dong LH,Cheng S,Zheng Z,et al. Histone deacetylase inhibitorpotentiated the ability of MTOR inhibitor to induce autophagic celldeath in Burkitt leukemia/lymphoma. J Hematol Oncol,2013 ;6 :53.
  • 6Shi Z, Li CY, Zhao S,et al. A systems biology analysis of autophagyin cancer therapy. Cancer Lett, 2013;337(2) : 149 - 160.
  • 7Xu G, Zhang W, Bertram P,et al. Pharmacogenomic profiling of thePI3K/PTEN-AKT-mTOR pathway in common human tumors. Int JOncol, 2004;24(4) :893 -900.
  • 8Shi WY, Xiao D, Wang Lfet al. Therapeutic metformin/AMPK acti-vation blocked lymphoma cell growth via inhibition of mTOR pathwayand induction of autophagy. Cell Death Dis, 2012 ; 3 :e275.
  • 9Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal inte-gration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol,2011;12(1) :21 -35.
  • 10Green AS, Chapuis N, Maciel TTyet al. The LKB1/AMPK signalingpathway has tumor suppressor activity in acute myeloid leukemiathrough the repression of mTOR-dependent oncogenic mRNA transla-tion. Blood, 2010;116(20) :4262 -4273.

同被引文献53

  • 1任琳琳,房静远.肿瘤中自噬的表观遗传学研究进展[J].中国癌症杂志,2011,21(6):484-488. 被引量:2
  • 2Siegel R,Naishadham D,Jemal A. Cancer statistics,2012 [J]. CA Cancer J Clin, 2012,62 ( 1 ) : 10-29.
  • 3Anglesio MS,Carey MS,K:bel M,et al. Clear cell carcinoma of the ovary:a report from the first Ovarian Clear Cell Symposium, June 24th, 2010 [J]. Gynecol Oncol, 2011,121 (2) : 407-415.
  • 4Japanese Gynecologic Cancer Committee. The annual report of the Japanese Society of Obstetrics and Gynecology 2010 [J]. Acta Obstet Gynecol Jpn,2012,64(7) : 1029-1141.
  • 5Okamoto A,Glasspool RM, Mabuchi S,et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary[J]. Int J Gynecol Cancer, 2014,24(9 Suppl 3 ) : 20-25.
  • 6Jin Y, Li Y, Pan L. The target therapy of ovarian clear cell carcinoma[J]. Onco Targets Ther,2014,7:1647-1652.
  • 7Takano M,Sugiyama T,Yaegashi N,et al. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary:a retrospective Japan Clear Cell Carcinoma Study[J]. Int J Gynecd Cancer,2008,18( 5 ) :937-942.
  • 8Penson RT, Dizon DS, Birrer MJ, et al. Clear cell cancer of the ovary [J]. Curr Opin Oncol, 2013,25(5 ) : 553-557,.
  • 9Yamamoto S,Tsuda H ,Takano M,et al. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma [J]. Virchows Arch, 2012,460( 1 ) :77-87.
  • 10Kuo KT,Mao TL,Jones S,et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma [J]. Am J Patho1,2009,174 (5), 1597-1601.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部